Joint Formulary & PAD

Ruxolitinib - Vitiligo

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Cream
Associated Icons :
NFD1
NICE
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Ruxolitinib
Indication :
Vitiligo
Group Name :
Keywords :
skin, dermatology, repigmentation, skin colour,
Brand Names Include :
Opzelura
Important Information :
Latest Additions Date From :
01 Oct 2025
Latest Additions Date To :
31 Oct 2025
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee does not recommend the use of ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over in line with NICE TA1088.

A NON-FORMULARY traffic light status has been applied to ruxolitinib cream for this indication

Other Indications

Below are listed other indications that Ruxolitinib is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Vitiligo.

  • No records returned.